Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
UMB Financial price target raised to $143 from $142 at Piper Sandler
Piper Sandler raised the firm’s price target on UMB Financial (UMBF) to $143 from $142 and keeps an Overweight rating on the shares. The firm ...
Piper Sandler Reaffirms Their Sell Rating on Ameriprise Financial (AMP)
In a report released today, John Barnidge from Piper Sandler maintained a Sell rating on Ameriprise Financial (AMP – Research Report), with a ...
Jefferies lifts Meta Platforms stock target to $810, maintains buy
Jefferies analyst Brent Thill increased the price target on Meta Platforms Inc. (NASDAQ: NASDAQ:META) shares, moving it up to $810 from the previous $715, while reiterating a Buy rating on the stock.